STAT1 and Dravet syndrome: This dose of JAKi normalized the activity of the IFN-JAK-STAT pathway in DS/CHD iPSC-derived cells, as assessed by immunoblotting analysis of p-STAT1 levels (Figures S6A, 2A, and 2B).